| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
WOBURN, Mass.—CNS drug specialist Cambria Biosciences announced the signing of a research collaboration agreement with Pfizer Animal Health to discover and develop new classes of antiparasitic drug products. As with the human population, there is a growing problem of drug resistance in animal parasites and microbes, which the new deal hopes to address. Financial terms were not disclosed but include milestone payments.
 
Cambria will use its chemical genetics platform to identify the molecular targets of Pfizer's therapeutic candidates, facilitating a better understanding of the compounds' modes of action and the development of more candidates. An often ignored component of the global drug industry, animal health products are a €4-billion market in Europe alone, which represents about a quarter of global sales, according to a May 2007 report in Animal Pharm.
 
"We are pleased that the experience and skills in chemical and genetic discovery that we have used to build our internal product pipeline for human neurological indications can also be leveraged to help companies such as Pfizer Animal Health improve the health and well being of animals around the world," says Dr. Leo Liu, Cambria president and CEO.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue